SCHEMBL1450754

SCHEMBL1450754

NC(=O)c1ccc2c(c1)[nH]c(=O)c1ccsc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 10/20 1.00
CSNK2A1 P68400 6/20 0.77
CSNK2A2 P19784 1/20 0.77
CSNK2B P67870 1/20 0.77
GAA P10253 2/20 0.45
KDM4E B2RXH2 1/20 0.45
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
MEN1 O00255 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
KMT2A Q03164 1/20 0.41
NEK1 Q96PY6 2/20 0.40
CHEK2 O96017 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1451202 0.87 CSNK2A1 (1.00) PARP1CSNK2A1CSNK2A2CSNK2B
SCHEMBL10132628 0.82 PARP1 (0.71) PARP1CSNK2A1CSNK2A2CSNK2BPARP15
SCHEMBL30577715 0.82 PARP1 (0.71) PARP1CSNK2A1CSNK2A2CSNK2BGAA
SCHEMBL13648691 0.82 PARP1 (0.71) PARP1CSNK2A1CSNK2A2CSNK2BPARP15
SCHEMBL1450212 0.82 PARP1 (0.71) PARP1CSNK2A1CSNK2A2CSNK2BGAA
SCHEMBL13648863 0.79 PARP1 (0.65) PARP1CSNK2A1CSNK2A2CSNK2BKDM4E
SCHEMBL11933181 0.79 PARP1 (0.65) PARP1CSNK2A1CSNK2A2CSNK2BKDM4E
SCHEMBL10132631 0.78 CSNK2A1 (0.69) PARP1CSNK2A1CSNK2A2CSNK2BGAA
SCHEMBL10132659 0.78 PARP1 (0.69) PARP1CSNK2A1CSNK2A2CSNK2BGAA
SCHEMBL10132587 0.78 PARP1 (0.69) PARP1CSNK2A1CSNK2A2CSNK2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
WO-2009097014-A2 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-08-06 WO disclosed
EP-2061765-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS Cylene Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263581-A1 FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PARP1, PARP11, TNKS PARP1 1/4885CSNK2A1 66/4885CSNK2A2 90/4885
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 PARP1 1797/4885CSNK2A1 6/4885CSNK2A2 11/4885
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A1 680/4885CSNK2A2 810/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885CSNK2A1 24/4885CSNK2A2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.